Table 3 Grades 1 and 2 drug-related adverse events (AEs)

From: Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

AE

0.6 mg m−2, n (n =9)

4.0 mg m−2, n (n =3)

5.3 mg m−2, n (n =7)

7.0 mg m−2, n (n =4)

Overall, n (%) (n =23)

Haematological AEs

 Lymphopenia

1

1

1

 

3 (13)

 Decreased haemoglobin

1

1

2

1

5 (22)

Nonhaematological AEs

     

 Nausea

2

1

1

1

5 (22)

 Vomiting

2

1

 

1

4 (17)

 Constipation

  

1

1

2 (9)

 Abdominal pain

   

2

2 (9)

 Peripheral neuropathy

4

1

2

1

8 (35)

 Hyperesthesia

   

1

1 (4)

 Asthenia

   

1

1 (4)

 Eye irritation

  

1

 

1 (4)

 Headache

 

1

  

1 (4)

 Intention tremor

  

1

 

1 (4)

 Mucosal inflammation

1

   

1 (4)

 Peripheral oedema

  

1

 

1 (4)

 Pyrexia

   

1

1 (4)

 Subileus

   

1

1 (4)

 Temperature intolerance

  

1

 

1 (4)

Back to article page